Streetbeat News

Products Services

SNY

Sanofi SA reported a Q1 operating income of 2.8 billion euros, a 14.7% decrease year-over-year, but beat EPS estimates with $0.97. Sales were $11.36 billion, exceeding expectations, driven by strong Dupixent and Beyfortus vaccine sales, despite challenges from generic competition and lower Lantus sales. R&D expenses rose, reflecting investment in vaccines and pharma. Sanofi expects a low single-digit business EPS decline in 2024 but predicts strong sales for Dupixent and mid-single-digit growth in vaccine sales. SNY shares rose 5.40% to $49.13.

Portfolio Pulse from Vandana Singh

April 25, 2024 | 1:47 pm

HAS

Nex and Hasbro have expanded their collaboration to launch a new suite of family games for the Nex Playground console. Three new games based on classic Hasbro titles will be released exclusively on Nex Playground, starting with HUNGRY HUNGRY HIPPOS: MOVE N' MUNCH.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:43 pm

RDY

Nestlé India and Dr. Reddy's Laboratories have announced a joint venture to expand the reach of their health science nutraceutical portfolio to consumers in India and other agreed territories. This strategic partnership aims to leverage both companies' strengths to enhance access to nutritional solutions.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:39 pm

MSFT

Microsoft Corporation (NASDAQ:MSFT) is set to release its Q3 earnings after the market closes on April 25, 2024, with analysts predicting an earnings per share of $2.82, up from $2.45 the previous year, and revenue of $60.8 billion. The company recently launched the Phi-3 Mini AI model. Shares rose 0.4% to $409.06. Analysts from Stifel, BMO Capital, Morgan Stanley, UBS, and Jefferies have maintained positive ratings with increased price targets.

Portfolio Pulse from Avi Kapoor

April 25, 2024 | 1:37 pm

MYNZ

Mainz Biomed announced positive topline results from a study evaluating novel mRNA biomarkers and a proprietary AI algorithm for colorectal cancer diagnostics, showing 92% sensitivity and 90% specificity. The study, which analyzed 690 subjects, including data from the ColoFuture and eAArly DETECT studies, demonstrated the potential to significantly improve early detection and treatment of pre-cancerous lesions.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:30 pm

MSFT

Microsoft Corp (NASDAQ:MSFT) is in focus ahead of its fiscal third-quarter earnings report, expected to post earnings of $2.82 per share on $60.804 billion in revenue. Last quarter, Microsoft exceeded estimates with an 18% revenue increase year-over-year, driven by AI integration across its tech stack. The company anticipates a slight decrease in Microsoft Cloud gross margin and significant capital expenditure increases. Revenue growth forecasts include 10-12% for Productivity and Business Processes, approximately 15% for Office 365, mid-to-high single digits for Office Consumer and LinkedIn, and 18-19% for Intelligent Cloud. Ahead of the earnings, MSFT shares are down 3.11% at $396.33, influenced by broader market sell-offs and caution after Meta's post-earnings drop. Analysts remain positive, with price target adjustments reflecting optimism about Microsoft's performance.

Portfolio Pulse from Adam Eckert

April 25, 2024 | 1:27 pm

MULN

Mullen Automotive, Inc. (MULN) has received CARB certification for its 2025 Mullen THREE, Class 3 EV truck, enabling eligibility for state EV incentives and aligning with the ACF regulation for zero-emission vehicle purchases by state and local government fleets. This follows a previous certification for the 2024 model year. The certification could significantly boost Mullen's market presence in CARB-compliant states, offering substantial rebates and tax credits to lower the net cost of the Mullen THREE.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:22 pm

POAI

Fujifilm and Predictive Oncology (POAI) have entered into a collaboration aimed at reducing protein interference in bacterial endotoxin detection testing of biopharmaceuticals. This partnership focuses on enhancing the safety and efficacy of biopharmaceutical products by improving the accuracy of endotoxin testing, which is crucial for ensuring the quality of drugs that are administered to patients.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:20 pm

ACON

Aclarion, Inc. (NASDAQ: ACON, ACONW) announced its Nociscan solution will be used in the LIFEHAB trial in Norway to evaluate diagnosis and treatment of chronic low back pain. The trial compares lumbar interbody fusion surgery with multidisciplinary rehabilitation and aims to begin enrollment in Q2 2024. Nociscan, a SaaS platform, helps physicians identify the source of low back pain by quantifying chemical biomarkers. This marks an important step towards achieving successful reimbursement in Norway's single-payer health system.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:20 pm

NVDA

Retail investors have seen significant returns on their investments in Nvidia Corp. (NASDAQ:NVDA), with the company's transition to an AI leader and its GPUs powering AI programs like OpenAI's ChatGPT being key growth drivers. Nvidia has surpassed Apple Inc., Tesla Inc., and the SPY ETF to become the top stock among retail investors. Despite a market sell-off in April, Nvidia's stock has shown resilience, supported by its role in the AI sector and partnerships with companies like Tesla Inc. and Meta Platforms Inc.

Portfolio Pulse from Benzinga Neuro

April 25, 2024 | 1:08 pm